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Pentraxin 3, ficolin-2 and lectin 
pathway associated serine protease 
MASP-3 as early predictors of 
myocardial infarction - the HUNT2 
study
Inga Thorsen Vengen1,*, Tone Bull Enger1,*, Vibeke Videm1,2 & Peter Garred3
The lectin complement pathway is suggested to play a role in atherogenesis. Pentraxin-3 (PTX3), 
ficolin-1, ficolin-2, ficolin-3, MBL/ficolin/collectin-associated serine protease-3 (MASP-3) and MBL/
ficolin/collectin-associated protein-1 (MAP-1) are molecules related to activation of the lectin 
complement pathway. We hypothesized that serum levels of these molecules may be associated with 
the incidence of myocardial infarction (MI). In a Norwegian population-based cohort (HUNT2) where 
young to middle-aged relatively healthy Caucasians were followed up for a first-time MI from 1995–
1997 through 2008, the 370 youngest MI patients were matched by age (range 29–62 years) and gender 
to 370 controls. After adjustments for traditional risk factors, the two highest tertiles of PTX3 and the 
highest tertiles of ficolin-2 and MASP-3 were associated with MI, with odds ratios (95% confidence 
interval) of 1.65 (1.10–2.47) and 2.79 (1.83–4.24) for PTX3, 1.55 (1.04–2.30) for ficolin-2, and 0.63 
(0.043–0.94) for MASP-3. Ficolin-1, ficolin-3 and MAP-1 were not associated with MI. In a multimarker 
analysis of all associated biomarkers, only PTX3 and MASP-3 remained significant. PTX-3 and MASP-3 
enhanced prediction of MI compared to the traditional Framingham risk score alone (AUC increased 
from 0.64 to 0.68, p = 0.006). These results support the role of complement-dependent inflammation in 
the pathophysiology of cardiovascular disease.
Atherosclerosis is a leading cause of morbidity and mortality in the industrialized world1. The typical clinical 
manifestations of advanced atherosclerosis are myocardial infarction (MI) and stroke, often happening without 
any prior clinical warning2,3. Prediction models based on clinical parameters, such as the Framingham score for 
calculating the 10-year risk for cardiovascular disease (CVD)4, are imprecise and 15–20% of patients admitted 
with MI have no major traditional risk factors5. Thus, early molecular or biochemical warning signals are urgently 
needed.
Chronic low-grade vascular inflammation plays an essential role in the initiation, progression and desta-
bilization of atherosclerotic plaques6. Among the innate immunity components, activation of the complement 
system has been associated with both pre-lesional stages and the progression of atherosclerotic lesions7. However, 
the mechanisms that drive the persistent non-resolving inflammation in the vessel wall remain incompletely 
understood.
Activation of innate immunity relies on a set of pattern recognition receptors (PRRs). Recently, long 
pentraxin-3 (PTX3), a PRR in the same family as C-reactive protein, has emerged as a new candidate risk 
marker of cardiovascular diseases8. Serum PTX3 levels have been associated with disease severity and mortality 
in patients with acute myocardial infarction9, ischemic stroke10, cancer11, acute respiratory distress syndrome12 
1Department of Laboratory Medicine, Children’s and Women’s Health, Norwegian University of Science and 
Technology, Trondheim, Norway. 2Department of Immunology and Transfusion Medicine, St Olavs University 
Hospital, Trondheim, Norway. 3Laboratory of Molecular Medicine, Department of Clinical Immunology, Sect. 7631, 
Rigshospitalet, Faculty of Health and Medical Sciences, University of Copenhagen, Trondheim, Norway. *These 
authors contributed equally to this work. Correspondence and requests for materials should be addressed to V.V. 
(email: vibeke.videm@ntnu.no)
Received: 12 October 2016
accepted: 18 January 2017
Published: 20 February 2017
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 7:43045 | DOI: 10.1038/srep43045
and sepsis13. PTX3 is released by multiple cells including monocytes/macrophages, neutrophils, and activated 
endothelial cells upon stimulation by IL-1 and TNF-α , cytokines markedly expressed in atherosclerotic lesions. 
PTX3 recognizes and binds to foreign molecules, leading to activation of the classical and lectin pathways of the 
complement cascade14,15.
Several studies have investigated the association between mannose-binding-lectin (MBL), the PRR and ini-
tiating factors of the lectin pathway of complement activation, and the risk of MI and cardiovascular disease. 
Previous results from our group demonstrated that MBL deficiency is associated with an increased risk of severe 
atherosclerotic disease16,17, suggesting that there exists a genetic predisposition related to the inflammatory sys-
tem that makes some individuals more susceptible to coronary artery disease. However, the results from various 
studies have been conflicting and the role of MBL remains debated18.
In addition to MBL, five other PRRs have been reported to be able to activate the lectin pathway by the binding 
to conserved structures present on various microorganisms or altered host cells: Collectin-10 (collectin liver 1, 
CL-L1, CL-10), collectin-11 (collectin kidney 1, CL-K1, CL-11), ficolin-1 (M-ficolin), ficolin-2 (L-ficolin) and 
ficolin-3 (H-ficolin). The PRRs are found in complex with the MBL/ficolin/collectin-associated serine proteases 
(MASPs), i.e. MASP-1, -2 and -319. In addition, two non-enzymatic proteins associated with the PRRs exists: 
MBL/ficolin/collectin-associated protein (MAP-1 or Map44) and small MBL-associated protein (sMAP, Map19 
or MAP-2). MASP-1 and MASP-2 are crucial for lectin pathway activation, whereas the biological role of MASP-3 
remains to be elucidated. Recent evidence indicates that MASP-3 is important for conversion of pro-factor 
D to active factor D, the initiating enzyme of the alternative pathway of complement, but it may also have a 
down-regulating effect on the lectin pathway20,21. sMAP plays a regulatory role in the activation of the lectin path-
way22, whereas MAP-1 has shown to inhibit the lectin pathway of complement activation23.
The complement system is an intricate system consisting of a complicated network of mediators with many 
interactive effects. We hypothesized that PRRs and their associated proteins in the lectin pathway regulate the 
immune response in the pathogenesis of atherosclerosis. Thus, the aim of the present study was to investigate 
the association between serum levels of PTX3, ficolins, MASP-3 and MAP-1 in young and middle aged relatively 
healthy individuals from the general Norwegian population with the future risk of MI. These might represent 
novel biomarkers for CVD and potential targets for the development of future treatment strategies.
Results
General characteristics investigation. Baseline characteristics of cases and controls are displayed in 
Table 1. Conventional cardiovascular risk factors were more frequent among cases: They had higher BMI, a more 
unfavourable lipid profile, and more often hypertension, diabetes, and family history of myocardial infarction. 
Cases were more often current smokers and had higher Framingham risk scores. Mean age for MI was 53 years 
(range 29–62).
26 (3.5%) and 10 (1.4%) patients had missing data on smoking and creatinine, respectively. Otherwise, miss-
ing values for background characteristics were generally low (< 0.2%).
Correlation between serum biomarkers and conventional clinical variables. In linear regression, 
the R2-values were generally low (< 0.1), indicating that the variables included explained a fraction of the plethora 
Cases Controls
P-value(n = 366) (n = 369)
Gender, female/male 87/279 88/281 0.98
Age, years 48 (47–48) 48 (47–48) 0.94
Age at MI, years 53 (29–62) — —
Body mass index, kg/m2 27.4 (27.0–27.8) 26.5 (26.1–26.9) 0.004
Hypertension 193 (53%) 162 (44%) 0.02 
  - Systolic blood pressure, mmHg 140 (139–142) 136 (135–138) < 0.001
  - Diastolic blood pressure, mmHg 85 (84–87) 83 (82–84) 0.002
Diabetes mellitus 13 (4%) 4 (1%) 0.03
Creatinine, μmol/L 90 (89–91) 90 (89–92) 0.67
Hypercholesterolemia 242 (66%) 145 (39%) < 0.001
Total cholesterol, mmol/L 6.8 (6.7–6.9) 6.0 (5.9–6.2) < 0.001
Triglycerides, mmol/L 2.53 (2.35–2.70) 2.05 (1.91–2.19) < 0.001
HDL cholesterol, mmol/L 1.18 (1.14–1.23) 1.28 (1.25–1.32) < 0.001
Smoking
 - Former/never 133 (37%) 195 (56%) < 0.001
 - Current 226 (63%) 155 (44%)
Framingham risk score 13 (13– 14) 11 (11–12) < 0.001
Family history of MI* 100 (27%) 54 (15%) < 0.001
Table 1.  Patient characteristics. Continuous variables are presented as median (95% CI), categorical variables 
as n (%). *Myocardial infarction before 60 years in first-degree relatives. HDL, high-density lipoprotein; MI, 
myocardial infarction.
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of variation in biomarker concentration. PTX3 and MAP-1 were not associated with any risk factors. Ficolin-2 
(p < 0.001), ficolin-3 (p = 0.03) and MASP-3 (p = 0.03) were associated with BMI, and ficolin-2 was also associ-
ated with smoking (p = 0.01). Ficolin-1 was associated with sex (p = 0.002) and creatinine (p = 0.03).
Association of serum biomarkers with the risk of future myocardial infarction. Serum con-
centrations of the biomarkers are displayed in Table 2. PTX3 (p < 0.001) and ficolin-2 (p < 0.001) were higher 
among cases, also after adjustments for classical risk factors. MASP-3 was lower among cases (p = 0.03) and this 
remained significant after adjustments for conventional CVD risk factors.
PTX3 was weakly correlated with ficolin-2 (Rho = 0.09, p = 0.02) and MASP-3 (Rho 0.09, p = 0.02). MASP-3 
was further correlated with ficolin-1 (Rho − 0.1, p = 0.01) and ficolin-3 (Rho − 0.17, p < 0.001). MAP-1 was cor-
related with ficolin-2 (Rho 0.14, p < 0.001).
The two highest tertiles of PTX3 were associated with an increased incidence of MI, also after adjustments for 
traditional risk factors (Table 3). The two highest tertiles of ficolin-2 were also associated with MI, however after 
adjustments, only the highest tertile remained significant. The two highest tertiles of MASP-3 were associated 
with a decreased risk of MI, but in the final model, this association remained only for the highest tertile. When 
including these three biomarkers in the same analysis, only the two highest tertiles of PTX3 and the highest tertile 
of MASP-3 remained significant in the analysis adjusted for conventional risk factors (Table 4).
When adding data on PTX3 and MASP-3 to the traditional Framingham score, the area under the 
receiver-operating characteristics curve (AUC) was significantly increased from 0.64 (0.60–0.68) to 0.68 (0.64–
0.72, p = 0.006, Fig. 1). The continuous net reclassification index showed significant improvement (0.35 (0.21–
0.49), p < 0.001). The integrated discrimination index was 0.04 (0.03–0.06), p < 0.001).
Discussion
The complement system constitutes an important component of innate immunity and atherosclerosis24. In the 
present study, we found that higher concentrations of PTX3 and ficolin-2, and lower concentrations of MASP-3 
were associated with increased risk of MI in middle-aged relatively healthy individuals, independent of conven-
tional CVD risk factors.
The associations of higher PTX3 and ficolin-2 levels with an increased risk of future MI may indicate an influ-
ence from a higher activity of the complement system. In line with our findings, higher serum PTX3 levels have 
been related to CVD risk factors, subclinical atherosclerosis and peripheral vascular diseases, as well as clinical 
CVD events and incident acute coronary syndromes - independently of CRP and CVD risk factors - in older as 
well as younger, apparently healthy populations8,25,26. PTX3 is rapidly induced at the tissue level and released into 
the blood at sites of MI, atherosclerosis, vascular damage or inflammatory lesions27–29. Thus, PTX3 is increasingly 
emerging as a potential biomarker of atherosclerosis and CVD8. Moreover, PTX3 has also been described as a 
marker of clinically more advanced cardiovascular disease30.
There is increasing evidence that PTX3 possesses atheroprotective properties, suggesting that PTX3 might 
balance the overactivation of a proinflammatory, proatherogenic cascade27. This was further supported by the 
demonstration that PTX3 deficiency promotes vascular inflammation and atherosclerosis31. The available evi-
dence therefore suggests that increased levels of PTX3 in patients with CVD reflects a protective physiologic 
response, which is correlated to disease severity.
A recent study demonstrated that ficolin-2 and MBL are present in human carotid plaques and recognize 
cholesterol crystals with subsequent activation of the lectin complement pathway32. The present study was not 
designed to elucidate causal relationships underlying the present associations with MI. However, in previous 
reports, neither genetic variations influencing blood ficolins nor PTX3 levels influenced the risk of MI17,33. The 
missing link between the genetic variants determining PTX3 and ficolin-2 levels with the risk of MI suggests that 
they act as markers of active atherosclerosis and complement activity rather than causal factors.
When performing a multimarker analysis together with PTX3 and MASP-3 as well as adjusting for conven-
tional risk factors, ficolin-2 was no longer significant. The present correlation matrix showed significant, albeit 
weak correlation between ficolin-2 and PTX3. Previous reports have shown that ficolins interact with PTX3 and 
MASPs15,34. Nevertheless, the lack of association of ficolin-2 to the risk of MI in the multimarker analysis may 
suggest that the information added by ficolin-2 was at least partially conveyed by the other markers.
Median concentration  
(±95% confidence interval) P-value
Missing, %Cases Controls Unadjusted* Adjusted
Pentraxin-3, ng/ml 2.96 (2.75–3.17) 2.16 (1.99–2.35) < 0.001 < 0.001 5.7%
Ficolin-1, μ g/ml 0.44 (0.41–0.46) 0.47 (0.44–0.51) 0.31 0.63 0
Ficolin-2, μ g/ml 5.07 (4.89–5.26) 4.57 (4.38–4.75) < 0.001 0.03 0
Ficolin-3, μ g/ml 25.4 (24.3–26.5) 24.2 (23.1–25.4) 0.09 0.78 0.4%
MASP-3, μ g/ml 4.50 (4.16–4.87) 4.98 (4.65–5.34) 0.033 0.03 2.0%
MAP-1, μ g/ml 0.17 (0.16–0.18) 0.18 (0.17–0.19) 0.39 0.18 0
Table 2.  Serum concentrations of the different biomarkers. *Unadjusted analysis: P-values from Mann-
Whitney U-test. Adjusted analysis: P-values from linear regression with robust standard errors with adjustments 
for age, sex, body mass index, creatinine, hypertension, hypercholesterolemia and smoking status. MASP-3, 
MBL/ficolin/collectin-associated serine protease-3: MAP-1, MBL/ficolin/collectin-associated protein-1.
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Patients suffering acute MI within the follow-up period presented with lower baseline MASP-3 concentra-
tions. Whereas the enzymatic properties of MASP-1 and MASP-2 in the activation of the lectin complement 
pathway have been described, the role of MASP-3 remains unclear35. Low levels of MASP-3 may be related to 
decreased synthesis or increased turnover. Furthermore, we cannot exclude that MASP-3 acts as a marker for 
other causal relationships. It has been shown that MASPs interact with ficolins, altering the effect of the com-
plement system. An effect of MASP-3 mediated through interactions with other molecules can therefore not be 
excluded.
In a recent study investigating the associations of components of the lectin pathway and low-grade inflamma-
tion, endothelial dysfunction, carotid intima-media thickness and CVD, MASP-3 was associated with endothelial 
dysfunction, independent of plasma MBL36. The authors suggested a potential role through non-complement 
pathways. The mechanisms underlying the association between lower MASP-3 concentrations and an increased 
risk of MI warrants further investigation.
The purpose of this study was not to evaluate the predictive performance of selected biomarkers. Nevertheless, 
the associations of PTX3, ficolin-2 and MASP-3 may uncover potential new causal mechanisms in the develop-
ment and progression of coronary heart disease and risk for MI, lead to the generation of new hypotheses and 
suggest improvements to existing explanatory models. Atherogenesis is characterized by multiple distinct path-
ways and molecular mechanisms, and our findings underscore the importance of the innate immune response 
and complement activation. A step further would be to investigate the causal relationships underlying the present 
associations.
On the other hand, we do not exclude that the described markers may prove useful in a predictive setting. 
Inclusion of biomarker data significantly improved the AUC, and indicators of predictive ability such as the net 
reclassification index and integrated discrimination index indicated potential usefulness in clinical prediction. 
There is a growing interest in developing a multimarker approach for identifying cardiovascular risk37–39. The 
novel markers may be potential targets that can be included in a multimarker panel for predicting CVD and iden-
tifying individuals at higher risk of MI, above that of traditional risk factors.
Our study has some limitations: We did not have accurate times to MI to our disposal, and despite exclusion of 
patients with clinical CVD, the group middle-aged relatively healthy individuals may constitute a heterogeneous 
study population with subclinical atherosclerosis at different stages.
In conclusion, elevated PTX3, elevated ficolin-2 and low MASP-3 concentrations were associated with 
increased risk of future MI in young to middle-aged relatively healthy Caucasians. Higher PTX3 and ficolin-2 
concentrations may indicate higher complement activity, especially related to the lectin pathway. However, 
Unadjusted Adjusted*
OR (95% CI) P-value OR (95% CI) P-value
Pentraxin-3
 Tertile I 1.0 1.0
 Tertile II 1.72 (1.18–2.50) 0.01 1.65 (1.10–2.47) 0.02
 Tertile III 2.87 (1.95–4.23) <0.001 2.79 (1.83–4.24) <0.001
Ficolin-1
 Tertile I 1.0 1.0
 Tertile II 1.02 (0.71–1.47) 0.9 1.10 (0.74–1.62) 0.64
 Tertile III 0.79 (0.55–1.14) 0.21 0.77 (0.52–1.13) 0.18
Ficolin-2
 Tertile I 1.0 1.0
 Tertile II 1.64 (1.13–2.36) 0.01 1.36 (0.92–2.01) 0.13
 Tertile III 2.00 (1.39–2.89) <0.001 1.55 (1.04–2.30) 0.03
Ficolin-3
 Tertile I 1.0 1.0
 Tertile II 1.36 (0.95–1.96) 0.10 1.20 (0.81–1.77) 0.36
 Tertile III 1.33 (0.92–1.91) 0.13 1.17 (0.79–1.73) 0.44
MASP-3
 Tertile I 1.0 1.0
 Tertile II 0.65 (0.45–0.93) 0.02 0.68 (0.46–1.01) 0.06
 Tertile III 0.66 (0.46–0.95) 0.02 0.63 (0.43–0.94) 0.02
MAP-1
 Tertile I 1.0 1.0
 Tertile II 1.23 (0.85–1.77) 0.27 1.16 (0.78–1.71) 0.46
 Tertile III 0.90 (0.63–1.30) 0.59 0.86 (0.59–1.27) 0.45
Table 3.  Logistic regression analysis. CI, confidence interval; MASP-3, MBL/ficolin/collectin-associated 
serine protease-3; MAP-1, MBL/ficolin/collectin-associated protein-1; OR, odds ratio. *Adjusted for sex, age, 
hypertension (yes/no), hypercholesterolemia (yes/no), smoking (never or previous/current), diabetes (yes/no) 
and body mass index.
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underlying mechanisms and potential use in a predictive setting merits further investigation. Nevertheless, our 
findings support the involvement of complement-dependent inflammation in the pathophysiology of cardiovas-
cular disease.
Materials and Methods
The present case-control study was generated from population data in the second wave of the Nord-Trøndelag 
Health (HUNT2) study, which was matched to data on incident acute MIs. The HUNT2 study was carried out 
in 1995–97 in the county of Nord-Trøndelag, Norway. This county is fairly representative for Norway as a whole. 
All inhabitants in the county of Nord-Trøndelag aged 13 and older were invited, and about 75,000 (70%) of those 
invited participated. Information was collected through comprehensive questionnaires and a clinical examina-
tion. A venous blood sample was drawn from attendants above 20 years. The inclusion process is described in 
detail elsewhere40. All methods were carried out in accordance with relevant guidelines and regulations. The 
study protocol was approved by the Regional Research Ethics Committee in Medicine, Central Norway (project 
numbers 157–1997 dated 06/11/1997 and 2009.1852 dated 11/20/2009) and the Data Inspectorate of Norway. 
Informed consent was obtained from all HUNT2 participants.
Data on MI hospitalization was collected from the two primary hospitals in the county of Nord-Trøndelag: 
Levanger Hospital and Namsos Hospital. From 1995 until 2000 data were registered retrospectively, and from 
2001 registration has been done prospectively. The European Society of Cardiology/American College of 
Cardiology guidelines were used for verification of MI diagnosis. The criteria are elevated troponin T or troponin 
I together with at least one of the following: (1) symptoms consistent with myocardial infarction and/or (2) ECG 
changes with development of significant Q wave and/or (3) ECG changes consistent with ischemia (ST segment 
elevation or depression).
Unadjusted Adjusted*
OR (95% CI) P-value OR (95% CI) P-value
PTX3
 Tertile I 1.0 1.0
 Tertile II 1.65 (1.12–2.44) 0.011 1.61 (1.07–2.44) 0.023
 Tertile III 2.93 (1.96–4.37) <0.0005 2.90 (1.89–4.47) <0.0005
Ficolin-2
 Tertile I 1.0 1.0
 Tertile II 1.51 (1.03–2.24) 0.037 1.24 (0.82–1.88) 0.31
 Tertile III 1.84 (1.24–2.73) 0.003 1.41 (0.92–2.16) 0.11
MASP-3
 Tertile I 1.0 1.0
 Tertile II 0.67 (0.45–1.0) 0.049 0.68 (0.45–1.05) 0.080
 Tertile III 0.56 (0.38–0.82) 0.003 0.52 (0.34–0.79) 0.002
Table 4.  Results from logistic regression including the three biomarkers that emerged as significant in 
primary analysis. CI, confidence interval; MASP-3, MBL/ficolin/collectin-associated serine protease-3; MAP-1, 
MBL/ficolin/collectin-associated protein-1; OR, odds ratio. *Adjusted for sex, age, hypertension (yes/no), 
hypercholesterolemia (yes/no), smoking (never or previous/current), diabetes (yes/no) and body mass index.
Figure 1. Comparison of the area under the receiver-operating characteristic curve (AUC) of the clinical 
model based on the Framingham risk score, with the model including pentraxin-3 and MBL/ficolin/
collectin-associated serine protease-3. 
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To be eligible for the present study, the participants of HUNT2 had to meet these criteria: available plasma and 
DNA as well as no previous self-reported cardiovascular disease. 57,133 persons met these criteria. By the end of 
2008, 1,689 HUNT2 participants had been admitted with MI and the 370 youngest were selected as cases in the 
present study. A younger population was particularly selected because the investigated parameters may be less 
influenced by confounding factors than in an elderly population with comorbidities. Controls matched on age 
(± 2 years) and gender were randomly selected, and all controls were at risk of MI at the time when their corre-
sponding case experienced MI. The same study cohort was described for a previous study investigating polymor-
phisms in MBL2 and ficolin genes in relation to the risk of MI17.
Clinical variables. Clinical variables such as height, weight and blood pressure were registered as previously 
described40, and body mass index (BMI) was calculated. Hypertension was defined as systolic blood pressure ≥ 
140 mmHg or as diastolic blood pressure ≥ 90 mmHg, or current use of antihypertensive medication. Information 
on other medication, such as statins was not available. Concentrations of glucose, creatinine and blood lipids were 
analysed by standard methods at the General Laboratory at Levanger Hospital. Hypercholesterolemia was defined 
as total cholesterol > 6.2 mmol/L. Smoking was categorized into two groups: never/former or current smokers. 
The Framingham risk score4 was calculated using the variables in the HUNT2 database (age, HDL-cholesterol, 
total cholesterol, systolic blood pressure, antihypertensive treatment, smoking and diabetes). A positive family 
history for coronary heart disease was defined as MI before 60 years in a first-degree relative.
Assays. Serum concentrations of ficolin-1, -2 and -3, PTX3, MASP-3 and MAP-1 were determined by sand-
wich ELISAs using specific in-house produced monoclonal antibodies as previously described13,21,41–44. All assays 
were optimized for automated analysis in the 384 well format on Biomek FX (Beckman Coulter, Fullerton, CA, 
USA).
Statistical analyses. Due to non-normal distribution of several variables, the Mann-Whitney U test 
was used to evaluate differences in continuous variables. The Chi square test was used to compare categorical 
variables.
Linear regression with robust standard errors was used to analyse how clinical variables were associated 
with serum concentration of the biomarkers. The clinical variables included were: age, gender, smoking (yes/
no), hypertension (yes/no), BMI, diabetes (yes/no), hypercholesterolemia (yes/no) and creatinine. Due to 
non-normality, either logarithmic transformation or Box-Cox transformation was performed, and extreme out-
liers were removed from the final models if they substantially altered the results.
Spearman correlation analysis was used to evaluate how the different biomarkers were related to each other. 
Associations between biomarker concentration and risk of MI were investigated using logistic regression. 
Biomarkers were divided into tertiles. Traditional risk factors included in the final models were sex, age, hyper-
tension (yes/no), hypercholesterolemia (yes/no), smoking (never or previous/current), diabetes (yes/no) and 
BMI.
Finally, the improvement in predictive utility was explored with an analysis of the AUC, continuous net reclas-
sification index and integrated discrimination index. Prediction of MI using the Framingham risk score alone was 
compared to a model combining the Framingham risk score with significant biomarkers from the multimarker 
analysis.
All tests were two-sided, and results are presented as medians or odds ratios with 95% confidence inter-
vals. P-values below 0.05 were considered statistically significant. All analyses were performed with Stata/MP 
for Mac, version 11.2, (Stata Corp., College Station, Texas, USA) and R, version 3.2.2 (Foundation for Statistical 
Computing, Vienna, Austria).
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